That said, well powered GWAS have only been available in the relatively recent past, and the above GWAS have found genome-wide significant variants in genes coding for existing osteoporosis drug targets, e.g., romosozumab (SOST), denosumab (RANKL) and raloxifene (ESR1). Here, SOST is linked to osteoporosis.